-$0.50 EPS Expected for Calithera Biosciences Inc (NASDAQ:CALA) This Quarter

Equities analysts expect Calithera Biosciences Inc (NASDAQ:CALA) to post ($0.50) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Calithera Biosciences’ earnings, with estimates ranging from ($0.54) to ($0.46). Calithera Biosciences reported earnings per share of ($0.51) in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to report its next quarterly earnings report on Thursday, March 5th.

On average, analysts expect that Calithera Biosciences will report full year earnings of ($2.11) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.98). For the next year, analysts anticipate that the firm will report earnings of ($1.78) per share, with EPS estimates ranging from ($2.01) to ($1.54). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.07.

Several equities analysts have recently weighed in on CALA shares. ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Monday. Citigroup set a $8.00 price objective on shares of Calithera Biosciences and gave the company a “hold” rating in a research report on Friday, August 9th. Finally, Zacks Investment Research downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Monday.

Shares of CALA traded up $0.12 during trading hours on Tuesday, hitting $3.49. The company had a trading volume of 25,545 shares, compared to its average volume of 386,456. The firm has a market cap of $167.24 million, a price-to-earnings ratio of -2.34 and a beta of 1.81. The business has a fifty day moving average of $2.95 and a 200-day moving average of $4.21. Calithera Biosciences has a 12 month low of $2.45 and a 12 month high of $6.90.

In other news, major shareholder Bvf Partners L. P/Il acquired 1,598,977 shares of Calithera Biosciences stock in a transaction on Tuesday, October 29th. The shares were purchased at an average cost of $2.60 per share, for a total transaction of $4,157,340.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Value Fund L. P. Biotechnology acquired 2,396,485 shares of Calithera Biosciences stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $3.33 per share, for a total transaction of $7,980,295.05. Corporate insiders own 17.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in CALA. Wedbush Securities Inc. acquired a new stake in Calithera Biosciences during the third quarter worth about $42,000. Beddow Capital Management Inc. acquired a new stake in Calithera Biosciences during the second quarter worth about $44,000. Tower Research Capital LLC TRC acquired a new stake in Calithera Biosciences during the second quarter worth about $56,000. Panagora Asset Management Inc. acquired a new stake in Calithera Biosciences during the second quarter worth about $60,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Calithera Biosciences during the second quarter worth about $63,000. Hedge funds and other institutional investors own 63.25% of the company’s stock.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.